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In Brief
The roles of AMPK in cancer and of
biguanides in its prevention or treatment
are controversial. Vara-Ciruelos et al. now
report that genetic loss of AMPK in T cells
accelerates T cell acute lymphoblastic
leukemia/lymphoma, whereas the
biguanide phenformin, but not metformin,
protects against its development in a cell-
autonomous, AMPK-dependent manner.
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AMPK acts downstream of the tumor suppressor
LKB1, yet its role in cancer has been controversial.
AMPK is activated by biguanides, such as metformin
and phenformin, and metformin use in diabetics has
been associated with reduced cancer risk. However,
whether this is mediated by cell-autonomous AMPK
activation within tumor progenitor cells has been un-
clear. We report that T-cell-specific loss of AMPK-a1
caused accelerated growth of T cell acute lympho-
blastic leukemia/lymphoma (T-ALL) induced by
PTEN loss in thymic T cell progenitors. Oral adminis-
tration of phenformin, but not metformin, delayed
onset and growth of lymphomas, but only when
T cells expressed AMPK-a1. This differential effect
of biguanides correlated with detection of phenfor-
min, but not metformin, in thymus. Phenformin also
enhanced apoptosis in T-ALL cells both in vivo and
in vitro. Thus, AMPK-a1 can be a cell-autonomous
tumor suppressor in the context of T-ALL, and phen-
formin may have potential for the prevention of some
cancers.
INTRODUCTION
The biguanides metformin and phenformin are derived from a
natural product of the plant Galega officinalis, used as an herbal
medicine in medieval Europe. Although introduced for treatment
of type 2 diabetes in the 1950s, their molecular mechanism only
began to emerge much later with findings that they inhibited
complex I of the respiratory chain, thus repressing mitochondrial
ATP synthesis (Bridges et al., 2014; El-Mir et al., 2000; Owen
et al., 2000). This increases cellular AMP:ATP ratios, leading to
activation of AMP-activated protein kinase (AMPK) (Hawley
et al., 2010; Zhou et al., 2001). Although the ability of metformin
to acutely inhibit hepatic glucose production is independent of690 Cell Reports 27, 690–698, April 16, 2019 ª 2019 The Author(s).
This is an open access article under the CC BY license (http://creativeAMPK (Foretz et al., 2010), its longer-term ability to reverse insu-
lin resistance is dependent upon phosphorylation of acetyl-
coenzyme A (CoA) carboxylase by AMPK (Fullerton et al., 2013).
Metformin is a cation with low membrane permeability and is
not taken up significantly by cells lacking transporters of the
organic cation transporter family (e.g., organic cation transporter
[OCT]1), although phenformin enters cells lacking such trans-
porters (Hawley et al., 2010). Once taken up, biguanides concen-
trate in the cytoplasm and then in mitochondria, driven by their
positive charge and themembrane potentials across the respec-
tive membranes (Owen et al., 2000).
AMPK is a sensor of cellular energy status; once activated, it
switches on catabolic pathways generating ATP and switches
off most biosynthetic pathways and progress through the cell cy-
cle (Ross et al., 2016). AMPK is only active after phosphorylation
by the tumor-suppressor kinase LKB1, originally identified as the
gene mutated in an inherited susceptibility to cancer termed
Peutz-Jeghers syndrome (Alessi et al., 2006). LKB1 is also
frequently mutated in spontaneous cancers, particularly lung
adenocarcinomas (Ross et al., 2016). This link between AMPK
and a tumor suppressor led to studies showing that diabetics
taking metformin had a lower cancer incidence than those on
other medications (Evans et al., 2005). Although supported by
several subsequent studies, the validity of that association has
been challenged (Suissa and Azoulay, 2014), and one controlled
trial of metformin in pancreatic cancer yielded negative results
(Kordes et al., 2015).
A key question concerns the extent to which the tumor-
suppressor functions of LKB1 aremediated by AMPK. One study
used mice lacking the Prkaa1 gene encoding AMPK-a1, the sole
catalytic subunit isoform expressed in lymphocytes. Consistent
with the idea that AMPK is a tumor suppressor, gene deletion
caused acceleration of lymphomas triggered by c-Myc expres-
sion in B cells (Faubert et al., 2013). A drawback with that
model was that AMPK-a1was deleted globally, not just in B cells.
Other studies suggested that the presence of either LKB1 (Algire
et al., 2011; Shackelford et al., 2013) or AMPK (Jeon et al., 2012;
Kishton et al., 2016) increased survival of tumor cells during
nutrient or oxygen deprivation or oxidative stress, thus exertingcommons.org/licenses/by/4.0/).
(legend on next page)
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tumor-promoting effects. Moreover, analysis of human cancer
genome databases showed that the genes encoding AMPK-a1
and AMPK-b2 are frequently amplified, consistent with roles in
promoting tumorigenesis (Ross et al., 2016).
To address the role of AMPK in T cell acute lymphoblastic leu-
kemia/lymphoma (T-ALL), we used a mouse model in which the
tumor suppressor gene Pten was deleted in T cell progenitors
(Hagenbeek and Spits, 2008), and generated lines with or
without additional T-cell-specific knockout of AMPK-a1. We
also tested the effects of biguanides in those mice.
RESULTS
Deletion of AMPK-a1 Accelerates Development of T-
ALL Induced by PTEN Loss
We generated mice with T-cell-specific deletion of PTEN and/or
AMPK-a1 by crossing Ptenfl/fl and Prkaa1fl/fl mice with Lck-Cre
transgenic mice. Because a1 is the only catalytic subunit isoform
expressed in T cells, with no a2 expression, even when a1 is
knocked out (Rolf et al., 2013), we refer to these as tPTEN/
tAMPK+/+ (AMPKwild type [WT]), tPTEN/ tAMPK+/ (heterozy-
gous deletion), or tPTEN/ tAMPK/ (homozygous deletion).
Mice were monitored daily until showing malaise, when thymus,
lymph nodes, and spleen were inspected for lymphoma. Tumors
were found either in the thymus only or in thymus and other
lymphoid organs.
As shown previously (Hagenbeek and Spits, 2008), mice with
T-cell-specific PTEN loss began to develop lymphomas at about
50 days of age, and almost all had developed tumors by
150 days (Figure 1A). Mice with T-cell-specific loss of AMPK-
a1 displayed no tumors up to 200 days. However, mice with
loss of both PTEN and AMPK-a1 developed tumors earlier,
and subsequent tumor-free survival was greatly reduced (Fig-
ure 1A). Surprisingly, mice with a single Prkaa1 allele behaved
similarly to those that had lost both alleles, except that the tu-
mors did not arise earlier. Median tumor-free survival was
94 days for PTEN-null mice with WT AMPK, and 75 days for
those with either heterozygous or homozygous deletion of
AMPK; the hazard ratios (Mantel-Haenszel), were 3.2 for hetero-
zygous and 3.6 for homozygous AMPK deletion.
To confirm that tumors arose earlier with homozygous AMPK
deletion, we examined thymus of some mice at 29–42 days of
age, before external signs of disease were evident. Incipient lym-Figure 1. T-Cell-Specific Loss of AMPK Accelerates Development of T
(A) Tumor-free survival curves for mice with T cells of the four different genotypes.
from those of the tPTEN/ tAMPK+/+ mice are shown.
(B) Distribution of cell sizes, estimated by forward scatter in flow cytometry, of
population of large cells in the tPTEN/ tAMPK/ sample indicates incipient ly
(C) Signaling via AMPK, Akt, and mTORC1 in lymphomas from three mice of eac
(D) Quantification of blots from all mice analyzed; for pAMPK, AMPKa, pAMP
pEBP1:4EBP1, n = 6 to 10.
(E) Quantification of blots (see Figure S1 for representative blots) analyzing expr
phomas of the indicated genotypes (n = 8–10).
(F) Expression of HIF1A and the glycolytic enzymes aldolase A (ALDOA) and lac
Quantification for all samples analyzed (HIF1A and LDHA, n = 3–5; ALDOA, n = 6
(G) Lactate levels in lymphoma-bearing thymus of the indicated genotypes.
(A–G) Mean values ± SEM are shown; those significantly different from the Cre-
different from tPTEN/ tAMPK+/+ mice are indicated by daggers (y).
692 Cell Reports 27, 690–698, April 16, 2019phoma could be recognized by the presence of a population of
large cells detectable by flow cytometry; Figure 1B illustrates
one example of this in a tPTEN/tAMPK/ mouse compared
with a normal Cre recombinase-negative (Cre-) control. The
presence of large cells wasmuch less frequent when PTEN alone
was deleted (2 of 14 cases, 16%) or when PTEN plus one AMPK
allele was deleted (1 of 6, 16%) than when PTEN and both alleles
of AMPK were deleted (13 of 22, 60%). The difference between
the PTEN-null and PTEN/AMPK-null mice was significant (one-
tailed Fisher’s exact test, p = 0.009).
Analysis of Protein Expression and Cell Signaling in T-
ALL Cells
We next monitored expression and/or phosphorylation of cell-
signalingmarkers in lymphomas, compared with normal thymo-
cytes from age-matched controls. Figure 1C shows thymus
blots from three representatives of each genotype, whereas
Figure 1D shows quantification of blots from all samples
analyzed. As expected, the levels of Thr172 phosphorylation
(pAMPK) and AMPK-a expression were reduced by around
50% in the AMPK heterozygote (although the pAMPK:AMPK-a
ratio did not change), and the AMPK-a and p-Thr172 signals
were almost eliminated by homozygous AMPK deletion (Figures
1C and 1D). Interestingly, PTEN deletion caused a significant
increase in the phosphorylation of the AMPK target acetyl
CoA carboxylase (ACC); similar results were obtained with WT
AMPK or heterozygotes, although ACC phosphorylation was
almost eliminated by homozygous deletion. As expected,
PTEN deletion increased phosphorylation of Akt at Ser473 in
tumors, but this did not increase further on AMPK deletion.
However, phosphorylation of two downstream targets of
mTORC1, 4EBP1 and RPS6, did increase further on AMPK
deletion, showing that deleting PTEN and AMPK had additive
effects to promote mTORC1 activity. PTEN-null lymphomas,
compared with normal thymocytes, also expressed high levels
of markers of proliferation (MKI67) and apoptosis (cleaved
PARP1), and low levels of the G1 cyclin-dependent kinase
inhibitor CDKN1B; these changes were further enhanced
when AMPK was knocked out (Figure 1E; representative blots
shown in Figure S1).
A key protein whose expression is controlled by mTORC1
signaling in T cells is hypoxia-inducible factor-1a (HIF1A) (Finlay
et al., 2012). PTEN-null thymic tumors expressed high levels of-ALL and Causes mTORC1 Hyperactivation
p values (log-rank, Mantel Cox) for survival curves that are significantly different
thymocytes from mice of two different genotypes at 37–42 days of age. The
mphoma.
h genotype.
K:AMPKa, pACC:ACC, and pAkt:Akt (Ser473), n = 8; for pRPS6:RPS6 and
ession of markers of cell proliferation and apoptosis in normal thymus or lym-
tate dehydrogenase A (LDHA). (Top) Western blots from three mice. (Bottom)
–10.
control by one-way ANOVA are indicated by asterisks, and those significantly
HIF1A, as shown previously (Grzes et al., 2017), and that
increased further on AMPK deletion (Figure 1F). Similar changes
of expression were observed for two transcriptional targets of
HIF1A, the glycolytic enzymes aldolase-A (ALDOA) and lactate
dehydrogenase-A (LDHA). Interestingly, lactate content was
also significantly increased in thymic lymphomas from mice
with deletion of both PTEN and AMPK compared with PTEN
alone (Figure 1G).
Deletion of AMPK Did Not Affect T Cell Development
We wondered whether tumorigenesis might be more rapid after
AMPK deletion because that affected T cell development,
perhaps by increasing the pool of PTEN-null T cell progenitors
that generate the tumors. However, flow cytometric analysis
revealed no difference in number or frequency of different
thymocyte sub-populations in tPTEN/ tAMPK+/+ or tPTEN/
tAMPK/ mice analyzed at 37–42 days (Figure S2). Similarly,
no differences were detected in cells from spleen or lymph
nodes (data not shown).
Effect of Metformin and Phenformin on Tumor-free
Survival In Vivo
The results above revealed that the absence of AMPK in T cell
progenitors accelerates the growth of lymphomas induced by
PTEN loss. We also tested the converse, i.e., whether AMPK
activation in vivo with a biguanide would exert an anti-tumor
effect. We first examined effects of delivery of metformin in
drinking water (calculated to deliver 400 mg/kg), starting
at 30 days of age in tPTEN/ tAMPK+/+ and tPTEN/
tAMPK/ mice. That dose is greater than that used in other
mouse studies (250 mg/kg), in which plasma metformin con-
centrations reached 3–12 mM, similar to those achieved in hu-
mans on the standard dose of z30 mg/kg (Chandel et al.,
2016). Despite that relatively high dose, there were no signif-
icant changes in survival caused by metformin, irrespective of
whether T cells expressed AMPK (Figure S3A). A likely expla-
nation was that metformin cannot activate AMPK in thymus
because of the lack of suitable transporters for cell uptake.
Consistent with that, metformin (although detectable in
plasma and liver) could not be detected in the thymus after
a single administration by oral gavage (Figure S3B). In addi-
tion, metformin treatment did not increase phosphorylation
of AMPK or ACC in lymphomas from tPTEN/ tAMPK+/+
mice (Figures S3C and S3D). Attempts to detect OCT family
members by western blotting were also unsuccessful, in
line with proteomic analyses of tPTEN/ T-ALL cells, in
which no expression of any member of the OCT family was
detected (data deposited with ProteomeXchange Consortium:
PXD006209 [Grzes et al., 2017]).
Unlike metformin, phenformin significantly increased tumor-
free survival, but that was dependent on cell-autonomous
expression of AMPK because no effect was seen in tPTEN/
tAMPK/ mice (Figure 2A). Phenformin was also detected after
oral gavage in thymus as well as plasma and liver (Figure 2B),
correlating with enhanced phosphorylation of Thr172 on AMPK
in lymphomas expressing AMPK-a1 (Figures 2C and 2D). Phos-
phorylation of ACC also appeared to increase, although that was
not statistically significant, perhaps because phosphorylationwas already high in mice with PTEN deletion. Phenformin treat-
ment also increased apoptosis in the lymphoma cells as shown
by a large increase in cleaved PARP1, although only when AMPK
was present (Figures 2C and 2D).
Effect of Biguanides on Tumor Cell Viability In Vitro
To investigate how phenformin protected against tumorigenesis
in an AMPK-dependent manner, we tested effects of biguanides
on tumor cell viability in vitro, both with primary PTEN-null T-ALL
cells from this project and with three previously established
PTEN-null T-ALL lines (M100, F04, and F15). Metformin reduced
the viability of all three established lines, although only at high
concentrations (Figure 3A); the half-maximal inhibitory concen-
tration (IC50) values ranged from 200 to 700 mM (peak plasma
concentration observed in vivo was 200 mM; Figure S3B). The
estimated IC50 value (±SEM) for primary lymphoma cells lacking
PTENwas similar at 700 ± 100 mM, whereas, in cells lacking both
PTEN and AMPK, it was higher at 1.8 ± 0.2 mM.
Phenformin was much more potent (Figure 3B; note different
scale on horizontal axis from Figure 3A); for the three established
cell lines, the IC50 values ranged from 3 to 7 mM (well below the
estimated peak plasma phenformin concentration of 50 mM; Fig-
ure 2B). For primary lymphoma cells lacking PTEN, the IC50 value
was similar (5 ± 1 mM), whereas for cells lacking both PTEN and
AMPK, the IC50 was higher (27 ± 5 mM). Figure 3C shows that
similar phenformin concentrations increased phosphorylation
of AMPK and ACC and decreased phosphorylation of RPS6 after
1 h, although the effect on AMPK was small.
Figure 3D shows western blots of the tPTEN/ T-ALL cell
lines treated with metformin (1 mM) or phenformin (10 mM)
for 24 h. Although phosphorylation of AMPK and ACC had re-
turned to baseline by that time, other downstream effects
were more evident. At that point, both biguanides still inhibited
mTORC1, as judged by reduced phosphorylation of RPS6,
S6K1, and 4EBP1 and reduced HIF1A expression, and both
also increased apoptosis, as assessed by PARP1 cleavage. Fig-
ure 3E shows the effects of phenformin on mTORC1 function in
primary lymphoma cells, revealing reduced RPS6 phosphoryla-
tion that was AMPK dependent because it was absent in AMPK
knockout cells.
Effects of Phenformin and Rapamycin on T-ALL Cells
In Vitro
To gain more clues as to how phenformin protected against
lymphoma, we further analyzed the three established T-ALL
lines in vitro. As expected for a respiratory-chain inhibitor, phen-
formin caused a progressive decrease in oxygen uptake (Fig-
ure 4A). This was associated with increased lactate output,
although the effect was not significant in F04 cells (Figure 4B).
As expected, the mTORC1 inhibitor rapamycin decreased cell
proliferation (Figure 4C). Phenformin caused increases in the
cellular ADP:ATP ratio in all three lines, whereas rapamycin
either had no effect or, in F15 cells, even decreased it
(Figure 4D). Both phenformin and rapamycin inhibited the
mTORC1 pathway, as assessed by reduced phosphorylation
of RPS6, S6K1, and 4EBP1 and reduced expression of
HIF1A and the glycolytic enzymes ALDOA and LDHA. Both
also increased expression of the G1 cyclin-dependent kinaseCell Reports 27, 690–698, April 16, 2019 693
Figure 2. Effect of Phenformin on Tumor-
free Survival and Signaling in the Thymus
In Vivo
(A) Effect of phenformin (300 mg/kg) on tumor-free
survival in tPTEN/ tAMPK+/+ or tPTEN/
tAMPK/ mice. The effect was significant as
shown (log-rank, Mantel-Cox) only in tumors with
wild-type AMPK-a1. Median survival was as fol-
lows: tPTEN/ tAMPK/, 75 days; tPTEN/
tAMPK/ plus phenformin, 70 days; tPTEN/
tAMPK+/+, 95 days; tPTEN/ tAMPK+/+ plus
phenformin, 119 days.
(B) Effects of time after oral gavage with phen-
formin on recovery (by LC:MS) in plasma (left)
and liver and thymus (right). Results are means ±
SEM (n = 3) in wild-type mice of 29–42 days
of age.
(C) Expression and phosphorylation of AMPK and
ACC and cleaved PARP1 in thymic lymphomas of
mice treated with or without phenformin (n = 3),
sampled when animals became unwell, or thymus
of age-matched controls.
(D)Quantification of blots in (C); results aremeans±
SEM. Results significantly different by one-way
ANOVA are indicated by asterisks; ns, not sig-
nificant.inhibitor CDKN1B, consistent with inhibition of cell proliferation.
However, a striking difference was that increased apoptosis, as
assessed by PARP1 cleavage, was only observed in cells
treated with phenformin and not with rapamycin (Figure 4E).
DISCUSSION
Although loss of AMPK-a1 alone did not cause lymphomas, it
accelerated development of lymphomas triggered by PTEN694 Cell Reports 27, 690–698, April 16, 2019loss. Because loss of AMPK-a1 was
T cell specific, we can be certain that
this was a cell-autonomous effect, un-
like a previous study (Faubert et al.,
2013) that used a B cell lymphoma
model. Surprisingly, the effects of het-
erozygous and homozygous deletion of
AMPK-a1 on tumor-free survival were
similar, showing that the tumor-sup-
pressor effect of AMPK displays
haploinsufficiency.
In this mouse model, AMPK, there-
fore, acts as a tumor suppressor. Rath-
mell’s group (Kishton et al., 2016) used
a different model of T-ALL in which
oncogenic NOTCH1 was expressed in
murine hematopoietic stem cells that
carried a floxed AMPK-a1 gene and
Cre recombinase driven by a tamox-
ifen-inducible promoter. The cells were
multiplied in irradiated mice and, then,
injected into irradiated, secondary re-
cipients. By treating the latter withtamoxifen, AMPK-a1 could be acutely deleted in the T-ALL
cells. In this model, knocking out AMPK-a1 reduced recovery
of T-ALL cells in spleen, lymph nodes, and bone marrow and
enhanced mouse survival (Kishton et al., 2016). Thus,
although the presence of two WT AMPK-a1 alleles protected
against T-ALL development in our model, once tumor cells
had developed, the presence of AMPK-a1 enhanced T-ALL
cell viability and reduced mouse survival. Thus, although
AMPK acts as a tumor suppressor during T-ALL development,
Figure 3. Cell Viability and Expression of
Markers during Treatment of Cells with
Biguanides
(A) Cell viability by flow cytometry (using DAPI to
label dead cells) for three established T-ALL cell
lines (M100, F04, and F15) and for primary lym-
phoma cells derived frommice with T-cell-specific
deletion of PTEN and/or AMPK after incubation for
24 h in the indicated concentrations of metformin.
Results (means ± SEM, n = 8) were fitted as
described in the STAR Methods.
(B) As shown in (A) but with phenformin.
(C) Phosphorylation of AMPK, ACCand RPS6 after
1 hr treatment with different concentrations of
phenformin (n = 2).
(D) Western blotting of various markers in
tPTEN/ T-ALL cell lines treated for 24 h with
1 mM metformin or 10 mM phenformin (n = 2).
(E) Effect of incubation with phenformin (1 h) on
mTORC1 signaling (pRPS6:RPS6 ratio) in T-ALL
cells with or without AMPK. Results are means ±
SEM (n = 4); significance of differences from
vehicle control are indicated by asterisks (ns, not
significant).once tumors have arisen, it switches to being a tumor
promoter.
Because Akt activation and AMPK inhibition activatemTORC1
by distinct mechanisms, it is not surprising that deleting
both PTEN and AMPK in T cells caused mTORC1 hyper-activa-
tion in the resultant lymphomas. This was associated with
increased expression of HIF1A and two of its downstream tar-
gets, the glycolytic enzymes ALDOA and LDHA. Consistent
with increased activation of glycolysis on AMPK deletion, lactate
levels were higher in the lymphomas with both PTEN and AMPK
deleted.
Because AMPK loss accelerated lymphoma development,
we tested whether the converse was true, i.e., whether phar-Cemacological activation of AMPK would
provide protection. Intriguingly, although
metformin (even at high doses) had no
effect, phenformin significantly delayed
tumorigenesis, although only when
AMPK-a1 was present in T cells. Thus,
the protective effect of phenformin in
T-ALL is both AMPK dependent and
cell autonomous. The failure of metfor-
min to provide protection correlated
with its inability to activate AMPK in
thymic lymphomas, most likely because
of the lack of expression of transporters,
such as OCT1; expression of OCT1 fam-
ily members was not detected in a pre-
vious proteomic analysis of PTEN-null
T-ALL cells (Grzes et al., 2017). More-
over, although we could detect metfor-
min by liquid chromatography-mass
spectrometry (LC-MS) in liver and
plasma, it was undetectable in thymictumors from the same animals. By contrast, we could detect
phenformin in liver, plasma, and thymic tumors. Thr172 phos-
phorylation on AMPK in thymus was also enhanced by phen-
formin, but not metformin. Unlike metformin, the more-hydro-
phobic phenformin is readily taken up by cells lacking OCT1
(Hawley et al., 2010). Indeed, phenformin was around 100-
fold more potent than metformin in reducing the viability of
T-ALL cells in vitro, correlating with greater potency in phos-
phorylation of AMPK and ACC. For phenformin, unlike metfor-
min, the IC50 for reduced viability in vitro was much lower than
the peak plasma concentrations observed in vivo.
In three established T-ALL cell lines, both phenformin and
rapamycin inhibited mTORC1; reduced expression of HIF1A,ll Reports 27, 690–698, April 16, 2019 695
Figure 4. Effects of Phenformin and Rapa-
mycin in Established tPTEN/ T-ALL Cell
Lines
(A) Effect of time of incubation with 10 mM phen-
formin on oxygen consumption rate (OCR); results
are means ± SEM (n = 3).
(B) Effect of phenformin treatment (10 mM) for
48 h on lactate output; results are means ± SEM
(n = 4–6).
(C) Effect of rapamycin (20 nM) on cell prolifera-
tion. Cells were grown for 48 h before 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) assay; results are percentage of the
control ± SEM (n = 6).
(D) Cellular ADP:ATP ratios in cell lines treated for
48 h with phenformin or rapamycin. Results are
means ± SEM (n = 6 for M100 cells; n = 8 for F01/
F15 cells).
(E) Analysis by western blot of cell lines (n = 2)
treated for 48 h with vehicle (DMSO), phenformin
(10 mM), or rapamycin (20 nM). In (B)–(D), results
significantly different from DMSO controls are
indicated by asterisks.ALDOA, and LDHA; and increased expression of the cell cycle
inhibitor CDKN1B. However, a striking difference was that only
phenformin triggered apoptosis, as assessed by PARP1 cleav-
age. Phenformin also triggered apoptosis in vivo, although
only when T-ALL cells expressed AMPK (Figures 2C and
2D). A potential explanation for that difference is that, although
phenformin and rapamycin have similar effects to downregu-
late glycolysis by inhibiting mTORC1 and hence HIF1A expres-
sion, phenformin also inhibits oxidative metabolism. Thus,696 Cell Reports 27, 690–698, April 16, 2019cells treated with rapamycin can switch
to oxidative metabolism to generate
ATP, but cells treated with phenformin
cannot and undergo apoptosis instead.
Consistent with this, phenformin, unlike
rapamycin, increased the cellular AD-
P:ATP ratios in all three T-ALL cell lines
and increased apoptosis in an AMPK-
dependent manner in lymphoma cells
in vivo.
If these findings are relevant in hu-
mans, biguanides may be useful in pre-
venting certain types of cancer in which
AMPK acts as a tumor suppressor,
especially those displaying hyper-
activated mTORC1. However, many tu-
mor cells may not express transporters
required for metformin uptake, and in
such cases, the more cell-permeable
biguanide phenformin should be
considered instead. Although it was
withdrawn for diabetes treatment
because of its association with lactic
acidosis, that side effect was quite
rare (z64 cases per 100,000 patient-
years [Crofford, 1995]). Although unac-ceptable for treatment of diabetes, this risk may be tolerable
in cancer.
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STAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
PTEN Santa Cruz Cat# Sc7974; RRID:AB_628187
pT172 (AMPK-a) Cell Signaling Technology Cat# 2531; RRID: AB_330330
AMPK, pan-a (for western blots) Cell Signaling Technology Cat# 2532; RRID: AB_330331
AMPK-a1 (for immunoprecipitation) (Woods et al., 1996) N/A
AMPK-a2 (for immunoprecipitation) (Woods et al., 1996) N/A
pACC1/pACC2 (S79/S212) Cell Signaling Technology Cat# 11818; RRID: AB_2687505
ACC Cell Signaling Technology Cat# 2280; RRID: AB_10694695
pAkt (T308) Cell Signaling Technology Cat# 9275; RRID:AB_329828
pAkt (S473) Cell Signaling Technology Cat# 4060; RRID:AB_2315049
Akt Cell Signaling Technology Cat# 2920; RRID:AB_1147620
p-RPS6 (S235/S236) Cell Signaling Technology Cat# 2211; RRID:AB_331679
RPS6 Cell Signaling Technology Cat# 2317; RRID:AB_2238583
p4EBP1 (T37/T46) Cell Signaling Technology Cat# 2855; RRID:AB_560835
4EBP1 Cell Signaling Technology Cat# 9644; RRID:AB_2097841
pS6K1 (T389) Cell Signaling Technology Cat# 9234; RRID:AB_2269803
S6K1 Cell Signaling Technology Cat# 2708; RRID:AB_390722
MKI67 Abcam Cat# ab15580; RRID:AB_443209
CDKN1B Cell Signaling Technology Cat# 3688; RRID:AB_2077836
PARP1 Cell Signaling Technology Cat# 9532; RRID:AB_659884
HIF1A Cell Signaling Technology Cat# 3716; RRID:AB_2116962
ALDOA Cell Signaling Technology Cat# 8060
LDHA Cell Signaling Technology Cat# 3582; RRID:AB_2066887
SMC1 Bethyl Cat# A300-055a; RRID:AB_2192467
CD4 PE-Cy7 BD Biosciences Cat# 552775; RRID: AB_394461
CD8a V450 BD Biosciences Cat# 560469; RRID:AB_1645281
CD71-PE BD Biosciences Cat# 553267; RRID:AB_394744
CD98-PE Ebiosciences Cat# 12-0981-82; RRID: AB_465793
CD62L FITC BD Biosciences Cat# 553150; RRID: AB_394665
CD44 APCeFluor 780 Ebiosciences Cat# 47-0441-82; RRID:AB_1272244
B220 V500 BD Biosciences Cat# 561227; RRID: AB_10562193
B220 PerCP-Cyanine5.5 Ebiosciences Cat# 45-0452-82; RRID:AB_1107006
Thy 1.1 APC Ebiosciences Cat# 17-0900-82; RRID:AB_469420
Chemicals, Peptides, and Recombinant Proteins
metformin hydrochloride Sigma-Aldrich D150959
phenformin hydrochloride Sigma-Aldrich P7045
rapamycin Sigma-Aldrich R0395
Proteinase K Roche 3115836001
Diisononyl phthalate Sigma-Aldrich 376663
Poly(dimethylsiloxane-co-methylphenylsiloxane) Sigma-Aldrich 378488
Thiazolyl Blue Tetrazolium Bromide Sigma-Aldrich M5655
Critical Commercial Assays
L-lactate assay kit Abcam Ab65331
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CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Grahame
Hardie (d.g.hardie@dundee.ac.uk).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mouse lines
Mice with LoxP sites flanking exon 5 of the Pten gene (Hagenbeek et al., 2004) were a gift from Hergen Spits. Mice with LoxP sites
flanking exons 4 and 5 of the Prkaa1 gene (Boudaba et al., 2018) were described previously. Transgenic mice expressing Cre recom-
binase from the Lck promoter (Takahama et al., 1998) were described previously. All mice used had been backcrossed onto the
C57BL/6J background for at least six generations. Both males and females were used; their ages are detailed in Figures. Mice
were housed in individually ventilated cages maintained at 20-22C with free access to food and water. All experiments with live
animals were approved by the Ethical Review Committee of the University of Dundee in accordance with the UK Animal (Scientific
Procedures) Act 1986.
Cell lines and primary cultures
Established PTEN null T-ALL cells (M100, F04, F15 (Hagenbeek et al., 2004)) were a gift from Hergen Spits. Primary T-ALL cells were
isolated by mechanical disruption of thymus using a syringe plunger and filtering the homogenized tissue through a 70 mm cell
strainer. Established cells and primary T-ALL cells were cultured in Iscove’s Modified Dulbecco’s Medium (IMDM) with 10% (v/v)
FBS and 1% (v/v) penicillin/streptomycin.
METHOD DETAILS
Mouse genotyping
Genotyping: a small piece of ear was digested with proteinase K (1 mg/ml) in 28 mM NaCl, 55 mM Tris, 0.1% SDS for 3 hr at 55C.
Samples (2 ml) were used to perform PCR.
Ptenfl/fl primers: forward, 50-GCCTTACCTAGTAAAGCAAC-30, reverse: 50-GGCAAAGAATCTTGGTGTTAC-30, which generated
products of 280 bp (Ptenfl) or 230 base pairs (wild-type). Prkaa1fl/fl primers: forward, 50-TTCAGGAAGGTATTGCTGCCATTAGG-30,
reverse: 50-GGATATGCCCAACCTCTCACGG-30, which generated products of 680 bp (PRKAA1fl) or 584 bp (wild-type)
Flow cytometry
Cells were staining with fluorochrome-conjugated antibodies to detect CD4, CD8, CD71, CD98, CD62L, CD44, B220 and/or Thy1.
Antibodies were diluted 1:200 and 1 3 106 cells were stained in 100 ml. Live cells were gated according to forward scatter and side
scatter. Data were acquired on a FACS Verse machine (Becton Dickinson) and analyzed using FlowJo software.
Cell survival assays using flow cytometry
Cells were incubated for 24 hr at the indicated biguanide concentration, washed with phosphate-buffered saline (PBS), incubated for
5 min with 40,6-diamidino-2-phenylindole (DAPI, 20 mg/ml) in PBS, and washed again with PBS. Samples were analyzed on a FACS
Verse flow cytometer (Becton Dickinson); this instrument is equipped with a volume sensor and gives absolute counts for all samples
analyzed. Cells were identified on the basis of forward angle light scatter (FSC) and side angle light scatter (SSC) and DAPI fluores-
cence measured by excitation at 405 nm and emission detected at 448 ± 45 nm. Cells were distinguished from debris on the basis of
FSC and SSC, and were further designated as alive or dead based on the absence or presence of DAPI, respectively.
MTT assays for cell proliferation
At the end of treatment (48 hr), Thiazolyl Blue Tetrazolium Bromide was added to the medium at 0.5 mg/mL for at least 24 hr. Water-
insoluble MTT formazan crystals were solubilized with acidified isopropanol and intensity measured colorimetrically at 570 nm.
Measurement of ADP:ATP ratios
The levels of ADP and ATP were measured by capillary electrophoresis as described previously (Hawley et al., 2010), and the results
expressed as ADP:ATP ratios.
LC:MS assays for biguanides in tissues
Plasma (50 ml) was mixed with 45 ml of acetonitrile and 5 ml of 12.5 mM metformin-d6 or 6.25 mM 1-phenylbiguanide hydrochloride
(internal standards). Plasma samples were centrifuged at 15,000 rpm for 10 min at 4C. Freeze-clamped livers were ground to pow-
der in liquid N2 using amortar and pestle. Tissue was dissolved at 50 mg/ml in acetonitrile. Sample (50 ml) wasmixed with 45 ml of water
plus 5 ml of 12.5 mMmetformin-d6 or 6.25 mM of 1-phenylbiguanide hydrochloride. Liver samples were centrifuged at 15,000 rpm for
10 min at 4 degrees. After T cells were harvested, 20 mg were diluted into 20 ml of water plus 25 ml of acetonitrile and 5 ml of 12.5 mMe2 Cell Reports 27, 690–698.e1–e4, April 16, 2019
metformin-d6 or 6.25 mM of 1-phenylbiguanide hydrochloride. Thymus samples were centrifuged at 15,000 rpm for 10 min at 4C.
Phenformin levels were measured using a TSQ Quantiva interfaced with an Ultimate 3000 Liquid Chromatography system
(ThermoScientific), equipped with a C18 column (Atlantis T3, 50x1 mm, ID 3 mm (Part No: 186003713, Waters). Mobile phase buffer
A consisted of 0.1% (v/v) formic acid and buffer B was 80% (v/v) acetonitrile. The column was maintained at 40C and was equili-
brated with 3% buffer B for 6 minutes at a constant flow rate of 0.06 mL/min. Aliquots of 1 ml of each sample were loaded onto
the column and compounds eluted with a linear gradient to 10% buffer B within 2 min, then to 30% B within 5 min. Buffer B was
then ramped up to 100%within 4 min and the column washed for a further 3 min. Eluents were sprayed into the TSQ Quantiva using
ion Max NG ion source with ion transfer tube temperature set to 350C and vaporizer temperature 125C. The TSQ Quantiva was run
in positive mode with a spray voltage of 2700, sheath gas 40 and Aux gas 10. Phenformin and internal standard (1-phenylbiguanide
hydrochloride) were measured using multiple reaction monitoring mode (MRM) with optimized collision energies and radio fre-
quencies previously determined by infusing pure compounds. Phenformin was measured using transitions (206.22 > 328.03 and
206.22 > 60.2) and internal standard wasmeasured using transitions (178.44 > 60.8 and 178.44 > 119.19). A standard curve was pre-
pared using phenformin with amounts ranging from 45 pM to 450 nMwith the internal standard spiked in at a constant amount of 312
pM. The standard curve was run prior to running the samples using the same conditions, and was used to calculate the amount of
phenformin in the samples. Three blanks were run between each sample to eliminate carryover. The same LC-MS system was used
to detect and quantify metformin. LC conditions were optimized using a HILIC column (Atlantis HILIC Silica T3, 503 1 mm, ID 3 mm
(Part No. 186002003, Waters). Mobile phase buffer A consisted of 0.1% (v/v) formic acid and buffer B was 2.5 mM ammonium
formate in 95% (v/v) acetonitrile. The columnwasmaintained at 32C andwas equilibrated with 100%buffer B for 5min at a constant
flow rate of 0.06 mL/min. Aliquots of 1 mL of each sample were loaded onto the column and an isocratic flow of 100% buffer B was
applied for 4 min. Elution of compounds was achieved by a linear gradient from 100%B to 10%Bwithin 5 min. Eluents were sprayed
into the TSQ Quantiva using ion Max NG as described for phenformin. The TSQ Quantiva was run in positive mode with a spray
voltage of 2700, sheath gas 35 and Aux gas 10. Metformin and deuteratedmetformin internal standard weremeasured usingmultiple
reaction monitoring mode (MRM) with optimized collision energies and radio frequencies previously determined by infusing pure
compounds. Two transitions (130.08 > 60.17 and 130.08 > 71.14) were used to monitor metformin and three (136.21 > 60.17,
136.21 > 77.17, 136.21 > 85.1) to detect deuterated metformin. A standard curve was generated with metformin ranging from
45 nM to 450 mM, and the internal standard spiked in at a constant amount of 232 pM. Three blanks were run between each sample
to eliminate carryover.
Measurements of cellular oxygen consumption
Cellular oxygen consumption rate was measured using a Seahorse XF24 Extracellular Flux Analyzer according to manufacturers’
instructions, as specified previously (Hawley et al., 2010).
Measurements of nutrient uptake by cells
Nutrient uptake was carried out using 1 3 106 cells resuspended in 0.4 mL of the medium specified below, layered over oil
(di-isononyl phthalate and poly(dimethylsiloxane-co-methylphenylsiloxane, 1:1). After uptake for 4 min, cells were centrifuged to
remove the medium, oil was aspirated and cell pellets resuspended in 1 mMNaOH. Radioactivity was measured using a scintillation
counter. Glucose uptake was measured individually in glucose-free DMEM (Life Technologies) containing the glucose analog [3H]-2-
deoxyglucose (1 mCi ml1). Glutamine or leucine uptake was measured in HBSS with Ca2+ and Mg2+ (Life Technologies) containing
[3H]-L-glutamine (1 mCi ml1) or [3H]-L-leucine (1 mCi ml1).
Lactate Assay
L-Lactate was measured with a colorimetric kit from Abcam (ab65331) following manufacturer’s instructions.
Other analytical procedures
SDS-PAGE was performed using precast Bis-Tris 4%–12% gradient polyacrylamide gels in the MOPS buffer system (ThermoFisher
Scientific). Proteins were transferred to nitrocellulose membranes using the iBlot 2 system (ThermoFisher Scientific). Membranes
were blocked for 1 hr in LICOR Odyssey blocking buffer. The membranes were probed with appropriate antibody (0.1–1 mg/ml)
in TBS-Tween and 2% (w/v) non-fat dried skimmed milk except where the blotting enhancement system was used (as per manufac-
turers’ instructions). Detection was performed using secondary antibody (1 mg/ml) coupled to IR 680 or IR 800 dye, and the
membranes scanned using the LICOR Odyssey IR imager. Protein concentrations were determined by Coomassie Blue binding
with bovine serum albumin as standard (Bradford, 1976).
QUANTIFICATION AND STATISTICAL ANALYSIS
Survival curves and other curve fitting
In vivo survival curves were plotted using using GraphPad Prism 6 for Mac OSX. In vitro cell survival data (Figures 3A and 3B) were
fitted to the equation: Y = 100-(100*X/(IC50+X)) by non-linear regression using GraphPad Prism 6 for Mac OSX.Cell Reports 27, 690–698.e1–e4, April 16, 2019 e3
Statistical analysis
Numbers of replicates and statistical significance is indicated in Figures or Figure legends. Numbers of replicates (n) refer to
biological replicates, i.e., the number of mice or independent cell cultures analyzed. Significances of differences were estimated
with GraphPad Prism 6 for Mac OSX, using 1-way or 2-way ANOVA as appropriate, and (unless stated otherwise) Sidak’s multiple
comparison test. Significant differences are indicated either by asterisks: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, or by
daggers: yp < 0.05, yyp < 0.01, yyyp < 0.001, yyyyp < 0.0001.e4 Cell Reports 27, 690–698.e1–e4, April 16, 2019
